MannKind Corporation (MNKD)
USD 4.76
(-2.56%)
USD 4.76
(-2.56%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 475.19 Million USD | 60.93% |
| 2022 | 295.28 Million USD | -8.06% |
| 2021 | 321.16 Million USD | 195.71% |
| 2020 | 108.6 Million USD | 15.88% |
| 2019 | 93.72 Million USD | -12.98% |
| 2018 | 107.7 Million USD | 27.35% |
| 2017 | 84.57 Million USD | -21.0% |
| 2016 | 107.06 Million USD | -15.31% |
| 2015 | 126.41 Million USD | -67.95% |
| 2014 | 394.43 Million USD | 52.5% |
| 2013 | 258.64 Million USD | 2.92% |
| 2012 | 251.31 Million USD | 25.94% |
| 2011 | 199.55 Million USD | -28.03% |
| 2010 | 277.25 Million USD | 12.07% |
| 2009 | 247.39 Million USD | -12.41% |
| 2008 | 282.45 Million USD | -48.02% |
| 2007 | 543.44 Million USD | 0.69% |
| 2006 | 539.73 Million USD | 136.34% |
| 2005 | 228.37 Million USD | 39.69% |
| 2004 | 163.48 Million USD | 29.88% |
| 2003 | 125.87 Million USD | 20.14% |
| 2002 | 104.77 Million USD | 0.0% |
| 2000 | 42.64 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 443.83 Million USD | -7.7% |
| 2024 Q1 | 480.87 Million USD | 1.2% |
| 2023 Q4 | 475.19 Million USD | 48.35% |
| 2023 Q1 | 298.13 Million USD | 0.97% |
| 2023 Q2 | 313.42 Million USD | 5.13% |
| 2023 Q3 | 320.32 Million USD | 2.2% |
| 2023 FY | 475.19 Million USD | 60.93% |
| 2022 Q4 | 295.28 Million USD | 0.49% |
| 2022 Q3 | 293.83 Million USD | 2.81% |
| 2022 FY | 295.28 Million USD | -8.06% |
| 2022 Q1 | 308.31 Million USD | -4.0% |
| 2022 Q2 | 285.79 Million USD | -7.3% |
| 2021 Q4 | 321.16 Million USD | 34.82% |
| 2021 Q3 | 238.2 Million USD | -5.77% |
| 2021 Q1 | 319.38 Million USD | 194.07% |
| 2021 FY | 321.16 Million USD | 195.71% |
| 2021 Q2 | 252.79 Million USD | -20.85% |
| 2020 Q2 | 102.78 Million USD | 28.14% |
| 2020 Q4 | 108.6 Million USD | 13.51% |
| 2020 Q1 | 80.21 Million USD | -14.42% |
| 2020 FY | 108.6 Million USD | 15.88% |
| 2020 Q3 | 95.68 Million USD | -6.91% |
| 2019 Q4 | 93.72 Million USD | -1.49% |
| 2019 FY | 93.72 Million USD | -12.98% |
| 2019 Q3 | 95.14 Million USD | 16.32% |
| 2019 Q2 | 81.79 Million USD | -18.98% |
| 2019 Q1 | 100.96 Million USD | -6.26% |
| 2018 FY | 107.7 Million USD | 27.35% |
| 2018 Q1 | 61.87 Million USD | -26.84% |
| 2018 Q4 | 107.7 Million USD | 137.47% |
| 2018 Q3 | 45.35 Million USD | -27.03% |
| 2018 Q2 | 62.15 Million USD | 0.45% |
| 2017 Q3 | 56.48 Million USD | -28.84% |
| 2017 FY | 84.57 Million USD | -21.0% |
| 2017 Q2 | 79.37 Million USD | -6.82% |
| 2017 Q1 | 85.18 Million USD | -20.43% |
| 2017 Q4 | 84.57 Million USD | 49.74% |
| 2016 Q2 | 139.43 Million USD | 49.49% |
| 2016 Q1 | 93.27 Million USD | -26.22% |
| 2016 FY | 107.06 Million USD | -15.31% |
| 2016 Q3 | 96.13 Million USD | -31.06% |
| 2016 Q4 | 107.06 Million USD | 11.37% |
| 2015 Q1 | 360.02 Million USD | -8.73% |
| 2015 Q4 | 126.41 Million USD | -54.53% |
| 2015 Q2 | 352.55 Million USD | -2.08% |
| 2015 Q3 | 278.01 Million USD | -21.14% |
| 2015 FY | 126.41 Million USD | -67.95% |
| 2014 Q2 | 236.3 Million USD | 5.23% |
| 2014 FY | 394.43 Million USD | 52.5% |
| 2014 Q4 | 394.43 Million USD | 1.97% |
| 2014 Q3 | 386.81 Million USD | 63.69% |
| 2014 Q1 | 224.55 Million USD | -13.18% |
| 2013 Q3 | 287.6 Million USD | 35.39% |
| 2013 FY | 258.64 Million USD | 2.92% |
| 2013 Q4 | 258.64 Million USD | -10.07% |
| 2013 Q2 | 212.42 Million USD | -1.29% |
| 2013 Q1 | 215.19 Million USD | -14.37% |
| 2012 FY | 251.31 Million USD | 25.94% |
| 2012 Q2 | 240.39 Million USD | -4.39% |
| 2012 Q3 | 210.33 Million USD | -12.51% |
| 2012 Q4 | 251.31 Million USD | 19.49% |
| 2012 Q1 | 251.42 Million USD | 25.99% |
| 2011 FY | 199.55 Million USD | -28.03% |
| 2011 Q3 | 224.01 Million USD | -1.9% |
| 2011 Q1 | 254.75 Million USD | -8.12% |
| 2011 Q2 | 228.35 Million USD | -10.36% |
| 2011 Q4 | 199.55 Million USD | -10.92% |
| 2010 Q2 | 239.55 Million USD | -1.52% |
| 2010 Q4 | 277.25 Million USD | -9.14% |
| 2010 FY | 277.25 Million USD | 12.07% |
| 2010 Q1 | 243.25 Million USD | -1.67% |
| 2010 Q3 | 305.14 Million USD | 27.38% |
| 2009 Q4 | 247.39 Million USD | -14.29% |
| 2009 FY | 247.39 Million USD | -12.41% |
| 2009 Q3 | 288.65 Million USD | 8.06% |
| 2009 Q2 | 267.12 Million USD | -3.11% |
| 2009 Q1 | 275.71 Million USD | -2.39% |
| 2008 Q4 | 282.45 Million USD | -14.83% |
| 2008 FY | 282.45 Million USD | -48.02% |
| 2008 Q1 | 465.4 Million USD | -14.36% |
| 2008 Q2 | 399.24 Million USD | -14.21% |
| 2008 Q3 | 331.63 Million USD | -16.94% |
| 2007 Q4 | 543.44 Million USD | 49.24% |
| 2007 FY | 543.44 Million USD | 0.69% |
| 2007 Q3 | 364.13 Million USD | -12.94% |
| 2007 Q2 | 418.23 Million USD | -13.33% |
| 2007 Q1 | 482.56 Million USD | -10.59% |
| 2006 FY | 539.73 Million USD | 136.34% |
| 2006 Q3 | 149.7 Million USD | 3.54% |
| 2006 Q4 | 539.73 Million USD | 260.54% |
| 2006 Q2 | 144.57 Million USD | -24.69% |
| 2006 Q1 | 191.99 Million USD | -15.93% |
| 2005 Q1 | 141.75 Million USD | -13.29% |
| 2005 FY | 228.37 Million USD | 39.69% |
| 2005 Q2 | 114.81 Million USD | -19.0% |
| 2005 Q4 | 228.37 Million USD | -12.17% |
| 2005 Q3 | 260.02 Million USD | 126.47% |
| 2004 Q2 | 110.77 Million USD | -13.97% |
| 2004 Q3 | 181.79 Million USD | 64.11% |
| 2004 Q4 | 163.48 Million USD | -10.07% |
| 2004 Q1 | 128.76 Million USD | 0.0% |
| 2004 FY | 163.48 Million USD | 29.88% |
| 2003 FY | 125.87 Million USD | 20.14% |
| 2002 FY | 104.77 Million USD | 0.0% |
| 2000 FY | 42.64 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 68.067% |
| Alkermes plc | 2.13 Billion USD | 77.755% |
| Agenus Inc. | 313.91 Million USD | -51.379% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 87.592% |
| Aptorum Group Limited | 20.64 Million USD | -2202.306% |
| Ardelyx, Inc. | 297.57 Million USD | -59.688% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 37.927% |
| Bicycle Therapeutics plc | 595.34 Million USD | 20.181% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -544.756% |
| ChromaDex Corporation | 54.96 Million USD | -764.562% |
| Chimerix, Inc. | 212.77 Million USD | -123.335% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -1580.785% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -7.762% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 78.687% |
| Precision BioSciences, Inc. | 159.78 Million USD | -197.406% |
| Dyadic International, Inc. | 8.21 Million USD | -5681.535% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -1397.158% |
| Fortress Biotech, Inc. | 167.52 Million USD | -183.656% |
| Lantern Pharma Inc. | 43.64 Million USD | -988.715% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -194.538% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -3175.726% |
| Incyte Corporation | 6.78 Billion USD | 92.993% |
| IO Biotech, Inc. | 150.71 Million USD | -215.289% |
| Jaguar Health, Inc. | 50.76 Million USD | -836.111% |
| Novavax, Inc. | 1.85 Billion USD | 74.388% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -24.918% |
| Opthea Limited | 188.79 Million USD | -151.706% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 42.958% |
| ContextLogic Inc. | 423 Million USD | -12.34% |
| MiMedx Group, Inc. | 239.04 Million USD | -98.789% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -173.533% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -9091.982% |
| NextCure, Inc. | 129.41 Million USD | -267.181% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -780.845% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -1193.795% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -1371.156% |
| Vaxcyte, Inc. | 1.4 Billion USD | 66.248% |
| PDS Biotechnology Corporation | 59.39 Million USD | -700.13% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 25.814% |
| Pharming Group N.V. | 462.85 Million USD | -2.667% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -1128.537% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 24.398% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -2411.13% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -2411.13% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -187.441% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -949.303% |
| Acelyrin, Inc. | 742.69 Million USD | 36.017% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -7114.702% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -7321.49% |
| Summit Therapeutics Inc. | 202.94 Million USD | -134.147% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -538.93% |
| Senti Biosciences, Inc. | 119.48 Million USD | -297.708% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -108.108% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -182.563% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -5650.914% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -9854.359% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -1.28% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -284.3% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -72.831% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -0.499% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -4602.603% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -121.531% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -41872.726% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -14.826% |
| Immix Biopharma, Inc. | 19.92 Million USD | -2284.914% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -28.423% |
| MEI Pharma, Inc. | 41.37 Million USD | -1048.515% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -1366.389% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -39.437% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -305.373% |
| Fortress Biotech, Inc. | 167.52 Million USD | -183.656% |
| Precigen, Inc. | 151.04 Million USD | -214.611% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -1296.902% |
| AlloVir, Inc. | 190.79 Million USD | -149.061% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -26.231% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 6.128% |
| ImmuCell Corporation | 43.8 Million USD | -984.726% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 26.816% |
| Onconetix, Inc. | 88.82 Million USD | -435.004% |
| PureTech Health plc | 693.97 Million USD | 31.525% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -386.46% |
| Elevation Oncology, Inc. | 89.09 Million USD | -433.385% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -7562.012% |
| Seer, Inc. | 436.26 Million USD | -8.923% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -482.372% |
| Innoviva, Inc. | 1.24 Billion USD | 61.786% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -258.849% |
| ESSA Pharma Inc. | 149.12 Million USD | -218.664% |
| GlycoMimetics, Inc. | 45.31 Million USD | -948.621% |
| GT Biopharma, Inc. | 14.1 Million USD | -3268.049% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -54.339% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -96.604% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -0.697% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -837.33% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -399.095% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -75138.605% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 16.093% |
| Aptose Biosciences Inc. | 12.92 Million USD | -3577.279% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -2048.828% |
| Soligenix, Inc. | 9.79 Million USD | -4750.283% |
| Century Therapeutics, Inc. | 360.69 Million USD | -31.747% |
| Kura Oncology, Inc. | 448.93 Million USD | -5.85% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -74.609% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -2647.603% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -328.449% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -131.633% |
| Autolus Therapeutics plc | 375.38 Million USD | -26.591% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -88.843% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -33.789% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -867.186% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 28.124% |
| GRI Bio, Inc. | 2.95 Million USD | -15975.71% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -4380.791% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -178.684% |
| IGM Biosciences, Inc. | 423.41 Million USD | -12.231% |
| INmune Bio, Inc. | 57 Million USD | -733.666% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -113.566% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -466.108% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1719.507% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -6803.742% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -531.694% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -222.698% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -187.122% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 24.524% |
| Verastem, Inc. | 149.71 Million USD | -217.395% |
| Abeona Therapeutics Inc. | 64 Million USD | -642.474% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 7.216% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -207.657% |
| Histogen Inc. | 19.07 Million USD | -2391.47% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -1997.988% |
| Surrozen, Inc. | 46.08 Million USD | -931.246% |
| Organovo Holdings, Inc. | 6.34 Million USD | -7384.612% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -10929.007% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -229.937% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -3926.419% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -531.341% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -5477.932% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -30.92% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -2526.216% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -10.665% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -3667.908% |
| Apollomics, Inc. | 55.38 Million USD | -757.959% |
| Amarin Corporation plc | 831.68 Million USD | 42.863% |
| Mesoblast Limited | 669.15 Million USD | 28.985% |
| Turnstone Biologics Corp. | 112.81 Million USD | -321.219% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 17.466% |
| Synaptogenix, Inc. | 31.11 Million USD | -1427.297% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -3800.181% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 13.295% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -7992.249% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -6369.54% |
| Exelixis, Inc. | 2.94 Billion USD | 83.85% |
| Better Therapeutics, Inc. | 22.94 Million USD | -1971.211% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -30.356% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 39.751% |
| NLS Pharmaceutics AG | 1.84 Million USD | -25633.101% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -5855.882% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -3133.739% |
| Gritstone bio, Inc. | 177.76 Million USD | -167.312% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -398.216% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -2560.345% |
| Avid Bioservices, Inc. | 336.55 Million USD | -41.194% |
| Insmed Incorporated | 1.32 Billion USD | 64.266% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -4835.407% |
| MediWound Ltd. | 66.45 Million USD | -615.024% |
| OmniAb, Inc. | 401.98 Million USD | -18.213% |
| Alector, Inc. | 621.82 Million USD | 23.58% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -32.515% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -8735.961% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -738.21% |
| Zai Lab Limited | 1.03 Billion USD | 54.145% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 0.681% |
| Aura Biosciences, Inc. | 255.07 Million USD | -86.297% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 36.643% |
| Immunic, Inc. | 54.29 Million USD | -775.151% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -78.496% |
| Veracyte, Inc. | 1.13 Billion USD | 58.236% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -3919.342% |
| FibroGen, Inc. | 423.52 Million USD | -12.2% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -13426.843% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -9932.46% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -8652.186% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 95.829% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -5296.911% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 8.166% |
| TG Therapeutics, Inc. | 329.58 Million USD | -44.18% |
| Galecto, Inc. | 38.22 Million USD | -1143.095% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -1557.128% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 89.094% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -101.865% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -1812.881% |
| XBiotech Inc. | 227.24 Million USD | -109.114% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -398.216% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -233.238% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -66.202% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -271.629% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -24.398% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 68.129% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -30.248% |
| Vaxxinity, Inc. | 44.35 Million USD | -971.4% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 8.078% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -2453.547% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -55.777% |
| NexImmune, Inc. | 8.59 Million USD | -5429.449% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -4334.807% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -2674.491% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 98.563% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -2045.254% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -121042.085% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -174.16% |
| Ainos, Inc. | 31.84 Million USD | -1392.371% |
| Pluri Inc. | 39.52 Million USD | -1102.211% |
| Prothena Corporation plc | 696.38 Million USD | 31.762% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -68.143% |
| Celularity Inc. | 143.88 Million USD | -230.253% |
| Rallybio Corporation | 115.62 Million USD | -311.0% |
| Cue Biopharma, Inc. | 61.53 Million USD | -672.303% |
| MeiraGTx Holdings plc | 458.16 Million USD | -3.717% |
| Omeros Corporation | 378.26 Million USD | -25.624% |
| Humacyte, Inc. | 128.22 Million USD | -270.603% |
| Immunocore Holdings plc | 597 Million USD | 20.402% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -1420.196% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -593.416% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 54.711% |
| CalciMedica, Inc. | 12.18 Million USD | -3799.86% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -87.344% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -178.043% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -52.78% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 15.939% |
| Pulmatrix, Inc. | 33.95 Million USD | -1299.37% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -1650.527% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -237.36% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 63.474% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -265.006% |
| Cytokinetics, Incorporated | 824.31 Million USD | 42.352% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -2149.671% |
| Nutriband Inc. | 7.51 Million USD | -6221.515% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -501.867% |
| Vor Biopharma Inc. | 209.82 Million USD | -126.47% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 93.421% |
| Evogene Ltd. | 51.1 Million USD | -829.919% |
| ProKidney Corp. | 420.55 Million USD | -12.994% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -766.628% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -4891.43% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 13.028% |
| CorMedix Inc. | 82.05 Million USD | -479.086% |
| BioLineRx Ltd. | 63.92 Million USD | -643.368% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -18.042% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -1585.099% |
| Atai Life Sciences N.V. | 293.47 Million USD | -61.919% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -191.301% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -272.944% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 15.449% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -391.318% |
| MediciNova, Inc. | 66.26 Million USD | -617.064% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -440.317% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -10549.017% |
| GeoVax Labs, Inc. | 9.28 Million USD | -5018.892% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 19.216% |
| Biomea Fusion, Inc. | 199.92 Million USD | -137.686% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 75.031% |
| Mereo BioPharma Group plc | 66.49 Million USD | -614.594% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 2.04% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 22.465% |
| Absci Corporation | 234.48 Million USD | -102.66% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -6396.213% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -39.809% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -187.856% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 9.713% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -71.124% |
| Allakos Inc. | 243.61 Million USD | -95.065% |
| Imunon, Inc. | 21.91 Million USD | -2068.065% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -84.404% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 23.542% |
| BioAtla, Inc. | 119.65 Million USD | -297.13% |
| NLS Pharmaceutics AG | 1.84 Million USD | -25633.101% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -14657.702% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 26.078% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -395.333% |
| XOMA Corporation | 234.3 Million USD | -102.815% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -114.793% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -277.609% |
| aTyr Pharma, Inc. | 122.06 Million USD | -289.293% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -208.765% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 18.108% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 3.105% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -330.164% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -3035.056% |
| Akari Therapeutics, Plc | 4.35 Million USD | -10811.55% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -2689.157% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 72.584% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -15308.565% |
| UroGen Pharma Ltd. | 178.31 Million USD | -166.5% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -0.948% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -85411.098% |
| Orgenesis Inc. | 14.55 Million USD | -3165.517% |
| Entera Bio Ltd. | 11.76 Million USD | -3939.082% |
| GH Research PLC | 226.3 Million USD | -109.986% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -768.83% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -342.308% |
| Xencor, Inc. | 952.69 Million USD | 50.121% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -6004.984% |
| Replimune Group, Inc. | 487.72 Million USD | 2.568% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -5787.657% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 26.717% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -15308.565% |
| Portage Biotech Inc. | 7.77 Million USD | -6008.729% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -10549.017% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -71.586% |
| OncoCyte Corporation | 74.89 Million USD | -534.511% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -23271.374% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -8111.981% |
| Purple Biotech Ltd. | 44.3 Million USD | -972.633% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -1292.481% |
| scPharmaceuticals Inc. | 94.47 Million USD | -402.967% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -2533.412% |
| HilleVax, Inc. | 344.43 Million USD | -37.965% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -14862.154% |
| Tharimmune, Inc. | 10.94 Million USD | -4241.138% |
| Genprex, Inc. | 10.67 Million USD | -4353.342% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 4.232% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -393.702% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -19487.716% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -11308.108% |
| OKYO Pharma Limited | 1.54 Million USD | -30731.707% |
| Savara Inc. | 177.56 Million USD | -167.621% |
| Curis, Inc. | 77.28 Million USD | -514.888% |
| Daré Bioscience, Inc. | 21.28 Million USD | -2132.841% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -643.091% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -5776.799% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -2353.141% |
| BeiGene, Ltd. | 5.8 Billion USD | 91.814% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -3804.988% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 77.248% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -32.755% |
| Erasca, Inc. | 395.29 Million USD | -20.213% |
| bluebird bio, Inc. | 619.16 Million USD | 23.251% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -10891.382% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 93.054% |
| DBV Technologies S.A. | 182.98 Million USD | -159.691% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -10891.382% |
| Moderna, Inc. | 18.42 Billion USD | 97.421% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -2508.541% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -4001.485% |
| Molecular Templates, Inc. | 35.38 Million USD | -1243.012% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -243.686% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 39.765% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -56.441% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -357.159% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -2.056% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -51.609% |
| MacroGenics, Inc. | 306.82 Million USD | -54.878% |
| RenovoRx, Inc. | 1.46 Million USD | -32314.598% |
| Adicet Bio, Inc. | 207.29 Million USD | -129.238% |
| Prime Medicine, Inc. | 193.85 Million USD | -145.136% |
| Aditxt, Inc. | 44.57 Million USD | -965.984% |
| Adagene Inc. | 115.72 Million USD | -310.613% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -10568.564% |
| Quantum-Si incorporated | 298.25 Million USD | -59.329% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 68.053% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -6064.099% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -35.276% |
| SciSparc Ltd. | 11.18 Million USD | -4149.669% |
| Vericel Corporation | 353.65 Million USD | -34.367% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -3791.044% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -735.137% |
| Generation Bio Co. | 374.75 Million USD | -26.801% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -86.597% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -199.683% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -39.205% |
| Invivyd, Inc. | 229.18 Million USD | -107.346% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 43.696% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -3804.891% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -160.54% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -2226.665% |
| 2seventy bio, Inc. | 565.42 Million USD | 15.958% |
| ADMA Biologics, Inc. | 329.18 Million USD | -44.357% |
| Clene Inc. | 52.34 Million USD | -807.889% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -709.063% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -265.835% |
| GeoVax Labs, Inc. | 9.28 Million USD | -5018.892% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 27.306% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -358.636% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -264.455% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -387.123% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -569.321% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -95.915% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 75.756% |
| Evaxion Biotech A/S | 12.88 Million USD | -3586.958% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -88.526% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 36.867% |
| Trevena, Inc. | 40.6 Million USD | -1070.294% |
| Surrozen, Inc. | 46.08 Million USD | -931.246% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -110.398% |
| Cingulate Inc. | 3.49 Million USD | -13510.388% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -2757.646% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -623.395% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -3966.865% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -76.971% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 36.552% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -277.465% |
| Clearmind Medicine Inc. | 4.32 Million USD | -10888.789% |
| Kronos Bio, Inc. | 213.27 Million USD | -122.806% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -197.4% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -5450.983% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -28.958% |
| Statera Biopharma, Inc. | 21.16 Million USD | -2144.71% |
| ImmunityBio, Inc. | 504.45 Million USD | 5.799% |
| Korro Bio, Inc. | 221.66 Million USD | -114.379% |
| Kineta, Inc. | 10.28 Million USD | -4522.099% |
| BioVie Inc. | 25.2 Million USD | -1785.082% |
| Codexis, Inc. | 136.56 Million USD | -247.975% |
| Celularity Inc. | 143.88 Million USD | -230.253% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 25.207% |
| Celcuity Inc. | 191.21 Million USD | -148.509% |
| Virax Biolabs Group Limited | 5.48 Million USD | -8565.22% |
| Cibus, Inc. | 544.41 Million USD | 12.713% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -277.459% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -2213.074% |
| IN8bio, Inc. | 33.7 Million USD | -1309.707% |
| Kodiak Sciences Inc. | 479.37 Million USD | 0.871% |
| Annexon, Inc. | 297.67 Million USD | -59.637% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -174.665% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -245.676% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -2163.602% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 84.107% |
| Eyenovia, Inc. | 28.77 Million USD | -1551.176% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -106.135% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -6478.045% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -679.959% |
| Arcellx, Inc. | 825.13 Million USD | 42.409% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -482.087% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -2.796% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -1445.359% |
| Moolec Science SA | 24.05 Million USD | -1875.769% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -53.228% |
| Geron Corporation | 394.07 Million USD | -20.585% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -367.209% |
| Royalty Pharma plc | 16.38 Billion USD | 97.099% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 20.13% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -6693.575% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -3850.99% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -110.209% |
| Humacyte, Inc. | 128.22 Million USD | -270.603% |
| Structure Therapeutics Inc. | 482.01 Million USD | 1.415% |
| 89bio, Inc. | 596.26 Million USD | 20.305% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -88.457% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -25586.378% |
| Genelux Corporation | 27.89 Million USD | -1603.646% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -431.524% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -107.122% |
| Notable Labs, Ltd. | 19.54 Million USD | -2331.8% |
| Liquidia Corporation | 120.43 Million USD | -294.581% |
| Mustang Bio, Inc. | 17.74 Million USD | -2578.379% |
| Immunovant, Inc. | 666.71 Million USD | 28.725% |
| Quantum-Si incorporated | 298.25 Million USD | -59.329% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -229.082% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -777.397% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -170.697% |
| Acasti Pharma Inc. | 73.3 Million USD | -548.292% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -10338.679% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1719.507% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 50.746% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -9056.175% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -1985.94% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -820.873% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -162.989% |
| PepGen Inc. | 143.05 Million USD | -232.185% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -1143.42% |
| United Therapeutics Corporation | 7.16 Billion USD | 93.37% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -2376.925% |
| Solid Biosciences Inc. | 164.93 Million USD | -188.105% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -7992.249% |
| Immuneering Corporation | 102.58 Million USD | -363.226% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -10929.007% |
| Silo Pharma, Inc. | 7.74 Million USD | -6034.642% |
| Belite Bio, Inc | 94.64 Million USD | -402.101% |
| XOMA Corporation | 234.3 Million USD | -102.815% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -103.783% |
| Bionomics Limited | 27.64 Million USD | -1618.675% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -18.384% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -342.506% |
| uniQure N.V. | 831.68 Million USD | 42.863% |
| Cassava Sciences, Inc. | 151.66 Million USD | -213.325% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -10568.564% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -73.503% |
| Forte Biosciences, Inc. | 38.98 Million USD | -1119.082% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -11566.7% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -1190.212% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -6478.045% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -13426.843% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -3919.948% |
| Altimmune, Inc. | 210.64 Million USD | -125.597% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 38.911% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -342.506% |
| Compugen Ltd. | 121.33 Million USD | -291.645% |
| Peak Bio, Inc. | 2.59 Million USD | -18202.082% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -175.754% |
| Benitec Biopharma Inc. | 52.21 Million USD | -810.167% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -39.004% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -1266.572% |
| Zura Bio Limited | 100.84 Million USD | -371.226% |
| PolyPid Ltd. | 15.37 Million USD | -2991.322% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -298.369% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -1266.572% |
| Instil Bio, Inc. | 325.63 Million USD | -45.932% |
| argenx SE | 4.54 Billion USD | 89.539% |
| Immunome, Inc. | 148.54 Million USD | -219.912% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -202.915% |
| Verona Pharma plc | 308.12 Million USD | -54.223% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -446.462% |
| Shattuck Labs, Inc. | 159.56 Million USD | -197.81% |
| CervoMed Inc. | 9.97 Million USD | -4665.074% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -152.153% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -4072.796% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -164.874% |
| Moolec Science SA | 24.05 Million USD | -1875.769% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -7667.872% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -174.769% |
| AnaptysBio, Inc. | 452.38 Million USD | -5.042% |
| Design Therapeutics, Inc. | 289.64 Million USD | -64.063% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -552.52% |
| NeurAxis, Inc. | 509.49 Thousand USD | -93167.883% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -8670.727% |
| Lumos Pharma, Inc. | 40.63 Million USD | -1069.344% |
| Achilles Therapeutics plc | 161.45 Million USD | -194.32% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -446.462% |
| 180 Life Sciences Corp. | 5.25 Million USD | -8935.083% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -574.731% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -5450.983% |
| Nutriband Inc. | 7.51 Million USD | -6221.515% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -86.582% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -138.432% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -523.521% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -720.495% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 9.751% |
| Palisade Bio, Inc. | 14.05 Million USD | -3281.711% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -125.967% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 67.446% |
| Neurogene Inc. | 222.57 Million USD | -113.502% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 26.511% |
| AEON Biopharma, Inc. | 6.84 Million USD | -6842.264% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -4.892% |
| Sesen Bio, Inc. | 189.17 Million USD | -151.196% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -74.791% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -3365.596% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 39.105% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -77.981% |
| Athira Pharma, Inc. | 160.24 Million USD | -196.545% |
| Vaccinex, Inc. | 3.63 Million USD | -12987.249% |
| HCW Biologics Inc. | 28.51 Million USD | -1566.563% |
| XOMA Corporation | 234.3 Million USD | -102.815% |
| Nektar Therapeutics | 398.03 Million USD | -19.387% |
| Arvinas, Inc. | 1.3 Billion USD | 63.575% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -2689.157% |
| Merus N.V. | 458.49 Million USD | -3.643% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -132.523% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -163.7% |
| Rezolute, Inc. | 132.73 Million USD | -258.0% |
| Clene Inc. | 52.34 Million USD | -807.889% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -3084.146% |
| BeyondSpring Inc. | 24.8 Million USD | -1815.503% |
| Synlogic, Inc. | 75.55 Million USD | -528.985% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -3906.053% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -4974.733% |
| Peak Bio, Inc. | 2.59 Million USD | -18202.082% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -171.801% |
| Krystal Biotech, Inc. | 818.35 Million USD | 41.933% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -97.638% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 34.527% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -13184.173% |
| Ikena Oncology, Inc. | 192.09 Million USD | -147.38% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -3453.148% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -307.759% |
| Gossamer Bio, Inc. | 311.91 Million USD | -52.348% |
| CohBar, Inc. | 16.36 Million USD | -2803.627% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -1251.415% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -6396.213% |
| Legend Biotech Corporation | 1.84 Billion USD | 74.294% |
| Mural Oncology plc | 301.74 Million USD | -57.483% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -1422.339% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -8265.565% |
| Disc Medicine, Inc. | 367.99 Million USD | -29.131% |
| Champions Oncology, Inc. | 26.13 Million USD | -1718.452% |
| REGENXBIO Inc. | 573.97 Million USD | 17.209% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -17447.381% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -207.799% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -3835.198% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -39.75% |
| Vaxart, Inc. | 91.83 Million USD | -417.476% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -693.267% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -220.372% |
| Cellectis S.A. | 334.27 Million USD | -42.16% |
| Longeveron Inc. | 12.17 Million USD | -3802.102% |
| Repare Therapeutics Inc. | 253.9 Million USD | -87.159% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 85.444% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -136.597% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 77.248% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -29142.954% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -71.112% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -191.357% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -242.5% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -1761.915% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 97.909% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 58.819% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -3791.044% |
| Veru Inc. | 50.59 Million USD | -839.202% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -943.176% |
| Cingulate Inc. | 3.49 Million USD | -13510.388% |
| Passage Bio, Inc. | 150.54 Million USD | -215.652% |
| Context Therapeutics Inc. | 16.06 Million USD | -2858.388% |
| Exicure, Inc. | 11.58 Million USD | -4003.61% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -26.366% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -193.982% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -2619.769% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -42.811% |
| Nuvalent, Inc. | 732.38 Million USD | 35.116% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -3079.841% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -430.627% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -3248.587% |
| OmniAb, Inc. | 401.98 Million USD | -18.213% |
| Anew Medical, Inc. | 19.45 Million USD | -2342.43% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -1677.999% |
| Lipocine Inc. | 23 Million USD | -1965.982% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -239.896% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -55.515% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -466.108% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -290.981% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -5888.633% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 46.14% |
| Ocugen, Inc. | 64.54 Million USD | -636.205% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -281.559% |
| Q32 Bio Inc. | 306.11 Million USD | -55.233% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -11192.728% |
| Alumis Inc. Common Stock | 89.61 Million USD | -430.284% |
| Equillium, Inc. | 50.53 Million USD | -840.427% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -531.954% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -1051.339% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -27838.805% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -1717.826% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -637.416% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -12649.761% |
| Dominari Holdings Inc. | 57.55 Million USD | -725.599% |
| Edesa Biotech, Inc. | 8.89 Million USD | -5245.047% |
| vTv Therapeutics Inc. | 11.01 Million USD | -4212.924% |
| Bio-Techne Corporation | 2.81 Billion USD | 83.108% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 49.292% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 41.438% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -71.141% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -1039.509% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 28.819% |
| Nkarta, Inc. | 378.88 Million USD | -25.42% |
| BioCardia, Inc. | 2.98 Million USD | -15808.872% |
| Iterum Therapeutics plc | 26.25 Million USD | -1709.658% |